,41 Although it is unlikely that statin treatment by itself will be sufficient to promote HIV control in the context of ART interruption, CD8+ T cell in vivo metabolic reprogramming with rosuvastatin could be used to potentiate the therapeutic efficacy of this cell population in immunotherapies aiming at HIV cure or remission, as it has been recently described in the case of PD-1 inhibitors for the treatment of cancer.42 This evidence concerns the gene CD8A and cancer.